Endocrine therapy resistance in ER+ metastatic breast cancer I have been randomized into the new drug arm of the CAMBRIA-2 study ESMO25 Breast Cancer Highlights: monarchE and NATALEE | Dana-Farber Cancer Institute
Should you avoid estrogen in your diet during breast cancer? Does your diet make a difference if you're on an endocrine therapy? ESMO25 Breast Cancer Highlights Panel Discussion | Dana-Farber Cancer Institute Medical updates in MBC: What you need to know
SERDs, SERMs, CERANs, and PROTACs Definition of SERD - NCI Dictionary of Cancer Terms - NCI Elacestrant belongs to a class of medications called selective estrogen receptor degraders (SERDs), offering a targeted approach
Tamoxifen Raloxifene Toremifene Clomiphene. ESMO: Clear air emerges between Roche SERD and its rivals #pharmanews #esmo In this video, Dr. Tufia Haddad answers questions about treatment options, recent drug approvals, clinical trials, symptoms and
Erika Hamilton, MD, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, discusses the safety results of the SERDs in premenopausal breast cancer: improving outcomes & treatment options
Erika Hamilton, MD, and Sarah Premji, MD, of Sarah Cannon Research Institute, discuss presentations from ESMO Congress Antibody-Drug Conjugates in the Management of HR+ and Triple-Negative Metastatic Breast Cancer Here's your Women's Health brief. Global experts issued unified guidance for IBD in pregnancy, supporting biologics and
ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer Understanding Clinical Trials in Breast Cancer Treatment AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer Dr Hamilton talks to ecancer about results from VERITAC-2, the first global phase 3 clinical trial of a PROTAC, a targeted therapy
What Are The Next-generation Chemoprevention Drugs For Breast Cancer? Are you interested in the latest developments in Elacestrant: A New Weapon Against Advanced Estrogen Receptor-Positive Breast Cancer Drug treatment for * Breast cancer * Endometrial Cancer * Prostate cancer * Alopecia * Benign prostatic hyperplasia explained
Erika Hamilton, MD, from Sarah Cannon Research Institute in Nashville, TN, discusses the landscape of oral Selective Estrogen Dr Maura Dickler, (Memorial Sloan Kettering Cancer Center, New York, USA) talks to ecancertv at AACR 2015 about a new ESMO25 Breast Cancer Highlights: evERA and SERENA6 | Dana-Farber Cancer Institute
Simple and short presentation for the mechanism of action, pharmacological actions, indications and adverse effects of selective SERENA-1 Parts K/L: camizestrant and ribociclib in ER+/HER2- breast cancer
AstraZeneca's oral SERD hits goal in phase 3 breast cancer trial Selective Estrogen Receptor Degraders (SERDs) for Metastatic Preliminary data on OP-1250 + palbociclib in advanced/metastatic ER+/HER- breast cancer
OP-1250: a small molecule oral complete estrogen receptor antagonist (CERAN) Patient eligibility in the AMEERA-6 trial of amcenestrant
Mafalda Oliveira, MD, PhD, Vall d'Hebron Institute of Oncology, Barcelona, Spain, provides an overview of the Phase II Sean Bohen, MD, PhD, Olema Oncology, San Francisco, CA, provides an overview of OP-1250, a complete estrogen receptor
Breast Cancer Breakthroughs: Fitting oral SERDs into early breast cancer treatment Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, comments on which groups of patients will be eligible to
EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer Get scanned lecture pdfs: SERENA-2: camizestrant vs fulvestrant in post-menopausal women with advanced ER+/HER- breast cancer
What Are The Next-generation Chemoprevention Drugs For Breast Cancer? Selective estrogen receptor degrader - Wikipedia In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN,
A drug that binds to and breaks down proteins called estrogen receptors (ERs), which are found inside the cells of female reproductive tissue, breast tissue, Hear from Eleonora Teplinsky, MD about the most recent drug approvals in metastatic breast cancer and how they impact each In today's top stories: - The FDA has rolled out its highly-touted generative AI tool, almost a month early, with a promise to reduce
Pharmacology-Estrogens and Antiestrogens Endocrine MADE EASY! As we countdown to #2024, let's look back at some of the top advances in breast and gynecologic cancers in 2023. *This is a list Selective Estrogen Receptor Modulator (SERM)
Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, discusses findings from the phase III AMEERA-6 trial Alana Welm, Ph.D. Senior Director of Basic Science Professor, Department of Oncological Sciences University of Utah, School of SERMs block estrogen receptors in the breast so that estrogen can't attach to the cancer cells and help them multiply. These medicines are
I have been randomized into the new drug arm of the CAMBRIA-2 study. That means I will get the new drug: Camizestrant, which Amid staff cuts, FDA looks to AI to 'optimise' reviews #news #pharmanews #biotechnews #asco2025 How Can I Understand Different Hormone Therapy Drugs For Breast Cancer? Are you curious about how hormone therapy drugs
Research Month: Antibody Drug Conjugates in Breast Cancer New drugs show rare promise against aggressive breast cancer How Are New Drugs Treating Metastatic Breast Cancer? - Breast Cancer Support Channel
Selective estrogen receptor degraders (SERDs) are a type of hormone therapy. These anti-estrogen drugs bind to the estrogen receptor in a tumor cell. They cause Trending in Women's Health: IBD in pregnancy, SERD win and more
Ask the expert: Metastatic breast cancer with Tufia C. Haddad, MD We had the pleasure of having Melanie Sisk on the show to demystify the complex world of emerging endocrine therapies, often Download Outcomes4Me: Watch the full interview here:
Dive into fulvestrant, an estrogen receptor degrader (SERD) used in hormone receptor-positive metastatic breast cancer. What's the Best Diet for Hormone Receptor-Positive Breast Cancer? The Ultimate Guide for HR+ SERDs are medications that treat ER-positive breast cancer. There's currently only one SERD that's FDA approved for use — fulvestrant
Tamoxifen is a medication that is commonly used in the treatment of certain types of breast cancer. It belongs to a class of drugs The landscape of oral SERDs and their potential in ER+ breast cancer Nikhil Wagle, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of resistance to endocrine therapies and
FDA approves elacestrant for ER-positive, HER2-negative, ESR1 SERMs and SERDs for Breast Cancer In this clip from Breast Cancer Breakthroughs Episode 11, medical oncologist Dr. Priya Rastogi discusses how she envisions new
How Can I Understand Different Hormone Therapy Drugs For Breast Cancer? With Aditya Bardia, MD, MPH. Drugs: Tamoxifen and Raloxifene Mechanism of action: Competitive inhibitor of estrogen binding Mixed agonist/antagonist action
One of the drugs is able to reach tumors that have spread to the brain. Speaker: Kevin Kalinsky, MD, MS Professor of Medicine Director, Glenn Family Breast Center Director, Breast Medical Oncology
Aditya Bardia, MD, MPH, discusses his research at the SABCS 2016 meeting. In a conversation with CancerNetwork®, Erica Mayer, MD, MPH, director of breast cancer research at Dana-Farber Cancer RV-471: novel PROTAC® estrogen receptor degrader, in ER+ breast cancer
Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, comments on the rationale and design of the ELECTRA trial
Focus On: Cancer Modeling Richard Baird, MD, PhD, University of Cambridge, Cambridge, UK, discusses findings from Parts K and L of the Phase I
Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers 8 Oral SERDs for Breast Cancer in Development - GoodRx
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Filipa Lynce, MD; and Ana C. Garrido-Castro, MD discuss SERM - Selective Estrogen Receptor Modulators Oral-Based SERDs Could Bolster QOL in ER+ HER2– Breast Cancer Treatment
Antonio Llombart-Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II selective estrogen receptor modulators (SERMs) The trial hit on progression-free survival, its primary endpoint, but is yet to show patients live longer on the drug candidate.
Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the monarchE and NATALEE trials, investigating CDK4/6 inhibitors Phase I Study of Investigational Drug Elacestrant (RAD1901) This review summarizes the currently available literature on this new class of drugs. Keywords: SERD; amcenestrant; breast cancer; camizestrant; elacestrant
Sean Bohen, MD, PhD, Olema Oncology, San Francisco, CA, shares preliminary data from a Phase Ib (NCT04505826) dose Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective SABCS 2024: Unlocking new targets with molecular degraders
How Are New Drugs Treating Metastatic Breast Cancer? In this informative video, we will discuss the latest advancements in the Top 5 Breast/GYN Cancer Advances in 2023: #2 Metastatic Breast Cancer Drug Approvals
ER degrader safe, with signs of antitumour activity against ER-positive breast cancer Antonio Llombart-Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, highlights the potential benefits of
15 Medicine of the week: Fulvestrant Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and
A selective estrogen receptor degrader or downregulator (SERD) is a type of drug that selectively binds to the estrogen receptor (ER) and induces its SERDs are a drug class that targets estrogen receptor alpha (ERα) for proteasome-dependent degradation. SERDs can induce receptor degradation by This session took place at 3:30 p.m. Wednesday, Dec. 11, 2025. It was an Educational Session. YOUTUBE CHAPTERS 0:00
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Brea In today's headlines – 21 October: - Has Roche taken a lead in the oral SERD category of breast cancer therapies with data
The Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2 Genentech's Giredestrant Becomes the First Oral SERD to Show
RAD1901 for Treatment of ER+ Breast Cancer Anti Cancer - Hormonal drugs [ Estrogens, SERMs, SERDs, Aromatase inhibitors etc] SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer Drugs.com provides accurate and independent information on more
Metastatic Breast Cancer Updates: SERDs, mTOR Inhibitors, and VIKTORIA-1 More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent New Oral Selective Estrogen Receptor Degraders Redefine
Selective estrogen receptor modulators